Sera Prognostics Inc (SERA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Sera Prognostics Inc (SERA) has a cash flow conversion efficiency ratio of -0.130x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-8.77 Million) by net assets ($67.62 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see how much is Sera Prognostics Inc worth for the company's overall valuation and market capitalisation.
Sera Prognostics Inc - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how Sera Prognostics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Sera Prognostics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Sera Prognostics Inc ranked by their cash flow conversion efficiency. See SERA operating cash to total liabilities to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Prime Electronics & Satellitics Inc
TW:6152
|
-0.095x |
|
Daekyo
KO:019680
|
-0.003x |
|
Kellton Tech Solutions Limited
NSE:KELLTONTEC
|
0.001x |
|
Trias Sentosa Tbk
JK:TRST
|
0.029x |
|
Global Data Centre Group
AU:GDC
|
0.644x |
|
IBU tec advanced materials AG
XETRA:IBU
|
0.255x |
|
Pioneer Credit Ltd
AU:PNC
|
0.010x |
|
TSKB Gayrimenkul Yatirim Ortakligi AS
IS:TSGYO
|
0.001x |
Annual Cash Flow Conversion Efficiency for Sera Prognostics Inc (2019–2025)
The table below shows the annual cash flow conversion efficiency of Sera Prognostics Inc from 2019 to 2025. View Sera Prognostics Inc (SERA) stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $75.41 Million | $-25.62 Million | -0.340x | -14.48% |
| 2024-12-31 | $47.80 Million | $-14.19 Million | -0.297x | +23.41% |
| 2023-12-31 | $70.16 Million | $-27.19 Million | -0.388x | -10.79% |
| 2022-12-31 | $98.94 Million | $-34.61 Million | -0.350x | -53.21% |
| 2021-12-31 | $138.56 Million | $-31.64 Million | -0.228x | +96.02% |
| 2020-12-31 | $2.94 Million | $-16.87 Million | -5.737x | -225.29% |
| 2019-12-31 | $10.96 Million | $-19.32 Million | -1.764x | -- |
About Sera Prognostics Inc
Sera Prognostics, Inc., a women's health company, discovers, develops, and commercializes blood-based biomarker tests, and predictive analytic products and services in the United States. The company develops the PreTRM test, a non-invasive blood test given to a pregnant woman, carrying a single fetus, during weeks 18 through 20 of gestation. It is also involved in the development of a pipeline of… Read more